ScholarIQanswers from OpenAlex & ORCID
Busyamas Chewaskulyong
ResearcherPublications, citations & collaboration network
Busyamas Chewaskulyong is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Busyamas Chewaskulyong have?
ScholarIQindexed works
Busyamas Chewaskulyong has 35 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Busyamas Chewaskulyong have?
ScholarIQcitation count
Busyamas Chewaskulyong has 17,715 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Busyamas Chewaskulyong?
ScholarIQh-index
Busyamas Chewaskulyong has an h-index of 12 in OpenAlex.
What is the i10-index of Busyamas Chewaskulyong?
ScholarIQi10-index
Busyamas Chewaskulyong has an i10-index of 15 in OpenAlex.
What is the OpenAlex record for Busyamas Chewaskulyong?
ScholarIQopenalex
The OpenAlex for Busyamas Chewaskulyong is on the source record.
What are the most-cited papers on Busyamas Chewaskulyong?
ScholarIQmost cited works
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok, Yi‐Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose, Yutaka Nishiwaki, Yuichiro Ohe, Jin-Ji Yang, Busyamas Chewaskulyong, Haiyi Jiang, Emma Duffield, Claire Watkins, Alison Armour, Masahiro Fukuoka
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer
Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata, Isamu Okamoto, Caicun Zhou, Byoung Chul Cho, Ying Cheng, Eun Kyung Cho, Pei Jye Voon, David Planchard, Wu‐Chou Su, Jhanelle E. Gray, Siow Ming Lee, Rachel Hodge, Marcelo Marotti, Yuri Rukazenkov, Suresh S. Ramalingam
Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC
Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E. Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong, Riyaz Shah, Manuel Cobo, Ki Hyeong Lee, Parneet Cheema, Marcello Tiseo, Thomas John, Meng‐Chih Lin, Fumio Imamura, Takayasu Kurata, Alexander Todd, Rachel Hodge, Matilde Saggese, Yuri Rukazenkov, Jean‐Charles Soria
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, Julien Mazières, Johan Vansteenkiste, H. Léna, Jesus Corral Jaime, Jhanelle E Gray, John D. Powderly, C. Chouaïd, Paolo Bidoli, Paul Wheatley‐Price, Keunchil Park, Ross A. Soo, Yifan Huang, Catherine Wadsworth, Phillip A. Dennis, Naiyer A. Rizvi, Luis Paz-Ares Rodríguez, Silvia Novello, Sandrine Hiret, Peter Schmid, Eckart Laack, Raffaele Califano, Makoto Maemondo, Sang‐We Kim, Jamie E. Chaft, David Vicente Baz, Thierry Berghmans, Dong‐Wan Kim, Veerle Surmont, Martin Reck, Ji‐Youn Han, Esther Holgado Martin, Cristóbal Belda-Iniesta, Yuichiro Oe, Antonio Chella, Akhil Chopra, G. Robinet, Héctor Soto Parrà, Michael J. Thomas, Parneet Cheema, Nobuyuki Katakami, Wu‐Chou Su, Young‐Chul Kim, Juergen Wolf, Jong-Seok Lee, Hideo Saka, Michele Stanislaw Milella, Inmaculada Ramos García, Anne Sibille, Takashi Yokoi, Eun Joo Kang, Shinji Atagi, E. Spaeth-Schwalbe, Makoto Nishio, Fumio Imamura, Nashat Gabrail, Rémi Veillon, Sofie Derijcke, Tadashi Maeda, Dylan M. Zylla, Kendra Kubiak, Armando Santoro, Ma. Noemi Uy, Sarayut Lucien Geater, Antoîne Italiano, Dariusz M. Kowalski, Fabrice Barlési, Yuh‐Min Chen, David R. Spigel, Busyamas Chewaskulyong, Ramón García Gómez, Rosa Álvarez, Chih-Hsin Yang, Te‐Chun Hsia, Fabrice Denis, Hiroshi Sakai, Mark Vincent, Kōichi Goto, Joaquim Bosch‐Barrera, Glen J. Weiss, Jean-Luc Canon, Christian W. Scholz, Massimo Aglietta, Hirotsugu Kemmotsu, Koichi Azuma, Penelope A. Bradbury, Ronald Feld, Abraham Chachoua, Jacek Jassem, Rosalyn A. Juergens, Ramon Palmero Sanchez, Albert Malcolm, Nandagopal Vrindavanam, Kaoru Kubota, Cornelius F. Waller, David Waterhouse, Bruno Coudert, Z. Mark
Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC
Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Y Cheng, Busyamas Chewaskulyong, R. Shah, Manuel Cobo, Ki Hyeong Lee, Parneet Cheema, Marcello Tiseo, Thomas John, Meng-Chih Lin, Fumio Imamura, Takayasu Kurata, Alexander Todd, Rachel Hodge, Matilde Saggese, Yuri Rukazenkov, Jean‐Charles Soria, FLAURA Investigators